XENE Live signals | Maximize Profits with Getagraph.com

SELL 103942 min ago

@ $49.08

Issued: 13 Feb 2024 @ 11:05

Return: -18.29%

Previous signal: Feb 12 - 15:25

Previous signal: Buy

Return: -0.13 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...

Stats
Today's Volume	245 032
Average Volume	363 530
Market Cap	3.02B
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.690 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.69
ATR14	$0.0440 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Von Seggern Christopher	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Aulin Sherry	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Kenney Christopher John	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Empfield James R.	Buy	65 000	Stock Option (Right to Buy)
2024-03-11	Robin Sherrington	Buy	65 000	Stock Option (Right to Buy)

INSIDER POWER
59.29
Last 100 transactions
Buy: 2 181 840 \| Sell: 619 411

Volume Correlation

Long: -0.40 (neutral)

Short: -0.53 (weak negative)

Signal:(37.08) Neutral

Xenon Pharmaceuticals Inc Correlation

10 Most Positive Correlations
PAIC	0.905
SVAC	0.827
GOODM	0.825
TLGT	0.818

10 Most Negative Correlations
RAVN	-0.9
NETE	-0.871
BOCH	-0.849
MMAC	-0.824
SHSP	-0.824
AMRB	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xenon Pharmaceuticals Inc Correlation - Currency/Commodity

-0.71
( moderate negative )

-0.87
( strong negative )

0.00
( neutral )

-0.90
( strong negative )

0.17
( neutral )

0.09
( neutral )

Xenon Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.54M (0.00 %)
EPS:	$-2.73

Q4	2023
Revenue:	$5.38M
Gross Profit:	$4.53M (84.18 %)
EPS:	$-0.640

Q3	2023
Revenue:	$0
Gross Profit:	$-1.73M (0.00 %)
EPS:	$-0.730

Q2	2023
Revenue:	$0
Gross Profit:	$-602 000 (0.00 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.